Trial Profile
Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-054
- Sponsors Merck Sharp & Dohme
- 29 Apr 2023 Results assessing the prognostic and predictive value of metformin including with respect to BRAF mutation status published in the European Journal of Cancer.
- 13 Sep 2022 Results (By Jan 17, 2022, 5-yr median follow-up and PD-L1+ subgroup N=853) assessing the efficacy of Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results assessing long-term quality of life analysis, presented at the 47th European Society for Medical Oncology Congress.